Drugs / IPV Vaccine SSI
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02347423 Comparator | Feb → Sep 2015 | poliomyelitis | Statens Serum Institut | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPV Vaccine SSI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02347423 ↗ |
| Route | Intramuscular | “receive one of four IPV formulations (three-times reduced dose [1/3 IPV-Al], five-times reduced dose [1/5 IPV-Al], ten-times reduced dose [1/10 IPV-Al], or IPV) intramuscularly...” PMID 28454674 ↗ Apr 2017 |